The importance of exosomal PDL1 in&#160;tumour immune evasion (Q92825452)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31965064%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

review article

1 reference

title

The importance of exosomal PDL1 in tumour immune evasion (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31965064%20AND%20SRC:MED&resulttype=core&format=json

evasion of host immune response

1 May 2020

main subject

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31965064%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Kathleen M Mahoney

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31965064%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Gordon J. Freeman

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31965064%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

publication date

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31965064%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Immunology

1 May 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31965064%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31965064%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31965064%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

page(s)

209-215

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31965064%20AND%20SRC:MED&resulttype=core&format=json

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Detection of Exosomal PD-L1 RNA in Saliva of Patients With Periodontitis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Circulating exosomal microRNAs as biomarkers of colon cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Exosomes derived from dendritic cells improve cardiac function via activation of CD4(+) T lymphocytes after myocardial infarction.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Combination cancer immunotherapy and new immunomodulatory targets

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Identification and characterization of an alternative cancer-derived PD-L1 splice variant

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Immuno-Oncology: Emerging Targets and Combination Therapies

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Clinical significance of PD-L1+ exosomes in plasma of Head and Neck Cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Elevated Soluble PD-L1 in Pregnant Women's Serum Suppresses the Immune Reaction

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

B7-1/2, but not PD-L1/2 molecules, are required on IL-10-treated tolerogenic DC and DC-derived exosomes for in vivo function.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Soluble B7-H1: differences in production between dendritic cells and T cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Mycotoxin verrucarin A inhibits proliferation and induces apoptosis in prostate cancer cells by inhibiting prosurvival Akt/NF-kB/mTOR signaling

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

sPD-L1 Expression is Associated with Immunosuppression and Infectious Complications in Patients with Acute Pancreatitis.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Age-dependent hypoxia-induced PD-L1 upregulation in patients with obstructive sleep apnoea

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Soluble Ligand of the Immune Checkpoint Receptor (sPD-L1) in Blood Serum of Patients with Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Soluble sPD-L1 and Serum Amyloid A1 as Potential Biomarkers for Lung Cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Is high serum programmed death ligand 1 level a risk factor for poor survival in patients with gastric cancer?

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

High-fidelity detection and sorting of nanoscale vesicles in viral disease and cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles.

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Analysis of Plasma EBV-DNA and Soluble Checkpoint Proteins in Nasopharyngeal Carcinoma Patients after Definitive Intensity-Modulated Radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41577-019-0264-Y

7 January 2021

10.1038/S41577-019-0264-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31965064%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

1 reference